EA025948B1 - КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR - Google Patents

КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR Download PDF

Info

Publication number
EA025948B1
EA025948B1 EA201391565A EA201391565A EA025948B1 EA 025948 B1 EA025948 B1 EA 025948B1 EA 201391565 A EA201391565 A EA 201391565A EA 201391565 A EA201391565 A EA 201391565A EA 025948 B1 EA025948 B1 EA 025948B1
Authority
EA
Eurasian Patent Office
Prior art keywords
kinase
ttok
rapamycin
carcinoma
dependent
Prior art date
Application number
EA201391565A
Other languages
English (en)
Other versions
EA201391565A1 (ru
Inventor
Кристин Фритч
Карлос ГАРСИЯ-ЭЧЕВЕРРИЯ
Сичжун Хуан
Савер-Мишель Мера
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46018130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA025948(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201391565A1 publication Critical patent/EA201391565A1/ru
Publication of EA025948B1 publication Critical patent/EA025948B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Настоящее изобретение относится к фармацевтической комбинации, включающей соединение-ингибитор фосфатидилинозит-3-киназы (PI3K), которое является производным 2-карбоксамидциклоаминомочевины, или его фармацевтически приемлемую соль и по меньшей мере один ингибитор мишени рапамицина (mTOR) у млекопитающих или его фармацевтически приемлемую соль; фармацевтической композиции, содержащей такую комбинацию; и к применению такой комбинации при лечении пролиферативных заболеваний, более предпочтительно заболеваний, зависимых от мишени рапамицина (mTOR) киназы у млекопитающих.

Description

(57) Настоящее изобретение относится к фармацевтической комбинации, включающей соединение-ингибитор фосфатидилинозит-3-киназы (ΡΙ3Κ), которое является производным 2-карбоксамидциклоаминомочевины, или его фармацевтически приемлемую соль и по меньшей мере один ингибитор мишени рапамицина (шТОК) у млекопитающих или его фармацевтически приемлемую соль; фармацевтической композиции, содержащей такую комбинацию; и к применению такой комбинации при лечении пролиферативных заболеваний, более предпочтительно заболеваний, зависимых от мишени рапамицина (шТОК) киназы у млекопитающих.

Claims (4)

1. Фармацевтическая комбинация, включающая:
a) соединение 1-({4-метил-5-[2-(2,2,2-трифтор-1,1-диметилэтил)пиридин-4-ил]тиазол-2-ил}амид) 2амида (8)-пирролидин-1,2-дикарбоновой кислоты или его фармацевтически приемлемую соль и
b) ингибитор тТОК, представляющий собой эверолимус (КАЭ001), или его фармацевтически приемлемую соль, для применения при лечении заболевания, зависимого от мишени рапамицина (тТОК) киназы у млекопитающих, где заболевание, зависимое от мишени рапамицина (тТОК) киназы у млекопитающих, представляет собой рак молочной железы, карциному легких, карциному поджелудочной железы, карци- 18 025948 ному толстой кишки и лимфому.
2. Фармацевтическая композиция, содержащая фармацевтическую комбинацию по п.1 для применения при лечении заболевания, зависимого от киназы тТОК, где заболевание, зависимое от мишени рапамицина (тТОК) киназы у млекопитающих, представляет собой рак молочной железы, карциному легких, карциному поджелудочной железы, карциному толстой кишки и лимфому.
3. Применение соединения 1-({4-метил-5-[2-(2,2,2-трифтор-1,1-диметилэтил)пиридин-4-ил]тиазол2-ил}амид) 2-амида (8)-пирролидин-1,2-дикарбоновой кислоты или его фармацевтически приемлемой соли и ингибитора тТОК, представляющего собой эверолимус (КАО001), или его фармацевтически приемлемой соли для получения лекарственного средства для лечения заболевания, зависимого от мишени рапамицина (тТОК) киназы у млекопитающих, где заболевание, зависимое от мишени рапамицина (тТОК) киназы у млекопитающих, представляет собой рак молочной железы, карциному легких, карциному поджелудочной железы, карциному толстой кишки и лимфому.
4. Способ лечения заболеваний, зависимых от мишени рапамицина (тТОК) киназы у млекопитающих, путем введения нуждающемуся в этом теплокровному животному соединения 1-({4-метил-5-[2(2,2,2-трифтор-1,1 -диметилэтил)пиридин-4-ил]тиазол-2-ил}амид) 2-амида (З)-пирролидин-1,2дикарбоновой кислоты или его фармацевтически приемлемой соли и ингибитора тТОК, представляющего собой эверолимус (КАБ001), или его фармацевтически приемлемой соли, где заболевание, зависимое от мишени рапамицина (тТОК) киназы у млекопитающих, представляет собой рак молочной железы, карциному легких, карциному поджелудочной железы, карциному толстой кишки и лимфому.
EA201391565A 2011-04-25 2012-04-23 КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR EA025948B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478572P 2011-04-25 2011-04-25
PCT/US2012/034647 WO2012148846A1 (en) 2011-04-25 2012-04-23 Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Publications (2)

Publication Number Publication Date
EA201391565A1 EA201391565A1 (ru) 2014-02-28
EA025948B1 true EA025948B1 (ru) 2017-02-28

Family

ID=46018130

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391565A EA025948B1 (ru) 2011-04-25 2012-04-23 КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR

Country Status (25)

Country Link
US (3) US20140066474A1 (ru)
EP (1) EP2701703A1 (ru)
JP (2) JP6086902B2 (ru)
KR (1) KR101925656B1 (ru)
CN (1) CN103491955B (ru)
AR (1) AR086481A1 (ru)
AU (2) AU2012250010A1 (ru)
BR (1) BR112013027486A2 (ru)
CA (1) CA2833962A1 (ru)
CL (1) CL2013003078A1 (ru)
CO (1) CO6801759A2 (ru)
EA (1) EA025948B1 (ru)
EC (1) ECSP13012994A (ru)
GT (1) GT201300263A (ru)
IL (1) IL229008A (ru)
MA (1) MA35038B1 (ru)
MX (1) MX2013012385A (ru)
NZ (1) NZ615593A (ru)
PE (1) PE20140601A1 (ru)
SG (1) SG193919A1 (ru)
TN (1) TN2013000392A1 (ru)
TW (1) TWI602567B (ru)
UA (1) UA110961C2 (ru)
WO (1) WO2012148846A1 (ru)
ZA (1) ZA201306973B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2776026A1 (en) * 2011-11-02 2014-09-17 Novartis AG 2-carboxamide cycloamino urea derivatives for use in treating vegf - dependent diseases
WO2014151147A1 (en) * 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
CA2929181A1 (en) * 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
US20170165246A1 (en) * 2014-02-11 2017-06-15 Novartis Ag Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
WO2015148626A1 (en) * 2014-03-26 2015-10-01 Millennium Pharmaceuticals, Inc. Treatment of fibrotic disorders
AU2015326392B2 (en) * 2014-10-03 2018-10-04 Novartis Ag Pharmaceutical compositions comprising alpelisib
US20160339030A1 (en) * 2015-05-19 2016-11-24 University Of Maryland, Baltimore Treatment agents for inhibiting hiv and cancer in hiv infected patients
GB202010627D0 (en) * 2020-07-10 2020-08-26 Qbd (Qs-Ip) Ltd Blocking method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096797A1 (en) * 2003-05-02 2004-11-11 Novartis Ag Inhibitors of phosphatidylinositol 3-kinase
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds
WO2010049481A1 (en) * 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98990A (pt) 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5151413A (en) 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
GB9125660D0 (en) 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
ZA935111B (en) 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935112B (en) 1992-07-17 1994-02-08 Smithkline Beecham Corp Rapamycin derivatives
US5256790A (en) 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
CA2175215C (en) 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
NZ277498A (en) 1993-12-17 1998-03-25 Novartis Ag Rapamycin derivatives
PT833828E (pt) 1995-06-09 2003-02-28 Novartis Ag Derivados de rapamicina
EP0937082A2 (en) 1996-07-12 1999-08-25 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
CN101360495B (zh) * 2005-11-14 2012-03-14 阿里亚德医药股份有限公司 对癌症病人给药mTOR抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004096797A1 (en) * 2003-05-02 2004-11-11 Novartis Ag Inhibitors of phosphatidylinositol 3-kinase
WO2010029082A1 (en) * 2008-09-10 2010-03-18 Novartis Ag Organic compounds
WO2010049481A1 (en) * 2008-10-31 2010-05-06 Novartis Ag Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAISUPARAT RISA, ET AL: "Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma.", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 68, no. 20, 15 October 2008 (2008-10-15), US, pages 8361 - 8368, XP002514946, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-08-0878 *
V. SERRA, B. MARKMAN, M. SCALTRITI, P. J.A. EICHHORN, V. VALERO, M. GUZMAN, M. L. BOTERO, E. LLONCH, F. ATZORI, S. DI COSIMO, M. M: "NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 68, no. 19, 1 October 2008 (2008-10-01), pages 8022 - 8030, XP055018423, ISSN: 00085472, DOI: 10.1158/0008-5472.CAN-08-1385 *

Also Published As

Publication number Publication date
CO6801759A2 (es) 2013-11-29
KR20140012147A (ko) 2014-01-29
TWI602567B (zh) 2017-10-21
JP2014513097A (ja) 2014-05-29
UA110961C2 (uk) 2016-03-10
MX2013012385A (es) 2013-11-04
NZ615593A (en) 2015-05-29
ZA201306973B (en) 2014-06-25
JP6086902B2 (ja) 2017-03-01
AU2012250010A1 (en) 2013-10-10
SG193919A1 (en) 2013-11-29
US20180085362A1 (en) 2018-03-29
IL229008A (en) 2017-11-30
JP2017061527A (ja) 2017-03-30
ECSP13012994A (es) 2013-12-31
EA201391565A1 (ru) 2014-02-28
US20170095463A1 (en) 2017-04-06
GT201300263A (es) 2015-11-24
CN103491955A (zh) 2014-01-01
TN2013000392A1 (en) 2015-01-20
CL2013003078A1 (es) 2014-05-30
CA2833962A1 (en) 2012-11-01
TW201244716A (en) 2012-11-16
WO2012148846A1 (en) 2012-11-01
AR086481A1 (es) 2013-12-18
CN103491955B (zh) 2015-12-23
AU2016202372B2 (en) 2017-07-20
KR101925656B1 (ko) 2018-12-05
AU2016202372A1 (en) 2016-05-05
EP2701703A1 (en) 2014-03-05
BR112013027486A2 (pt) 2017-02-14
MA35038B1 (fr) 2014-04-03
IL229008A0 (en) 2013-12-31
PE20140601A1 (es) 2014-05-24
US20140066474A1 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
EA025948B1 (ru) КОМБИНАЦИЯ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТ-3-КИНАЗЫ (PI3K) И ИНГИБИТОРА mTOR
RU2014120792A (ru) Способ лечения стромальных опухолей желудочно-кишечного тракта
EA201101507A1 (ru) Способы лечения солидных опухолей
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
EA201000091A1 (ru) ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
PH12015500719A1 (en) Gdf-8-inhibitors
EA201500265A1 (ru) Ингибиторы репликации вирусов гриппа
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
MX346186B (es) Inhibidores de proteina cinasas.
EA201792541A3 (ru) Ингибиторы рециркуляции желчных кислот для лечения гиперхолемии и холестатического заболевания печени
EA201391263A1 (ru) Комбинированные терапии гематологических опухолей
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
EA201200472A1 (ru) Сульфонамиды в качестве ингибиторов белков семейства bcl-2, предназначенные для лечения рака
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
MX2015000746A (es) Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k).
MX2013012588A (es) Inhibidores de cinasa.
MX2015017629A (es) Combinaciones farmaceuticas.
EA201290516A1 (ru) Гетероароматические производные соединения фенилимидазола в качестве ингибиторов фермента pde10a

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ RU